About Glycerol kinase 2
Glycerol kinase 2 (GK2) is a protein
from Homo sapiens identified by UniProt accession
Q14410, 553 residues long.
MolForge cross-references it against 0 known binders and
120 disease associations.
Target properties
| Protein name | Glycerol kinase 2 |
| UniProt accession | Q14410 |
| Gene | GK2 |
| Organism | Homo sapiens |
| Length | 553 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (120)
Diseases linked to this target (Open Targets).
- Myopia · score 0.32
- refractive error · score 0.31
- age at onset · score 0.28
- smoking status measurement · score 0.24
- smoking behavior · score 0.24
- Abnormality of refraction · score 0.20
- protein measurement · score 0.16
- azoospermia · score 0.11
- male infertility with teratozoospermia due to single gene mutation · score 0.11
- spermatogenic failure 10 · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14410-F1 | alphafold | PREDICTED | 91.97 | — |
Amino-acid sequence (553 residues)
MAAPKTAAVG PLVGAVVQGT NSTRFLVFNS KTAELLSHHK VELTQEFPKE GWVEQDPKEI LQSVYECIAR TCEKLDELNI DISNIKAVGV SNQRETTVIW DKLTGEPLYN AVVWLDLRTQ TTVEDLSKKI PGNSNFVKSK TGLPLSTYFS AVKLRWMLDN VRNVQKAVEE GRALFGTIDS WLIWSLTGGV NGGVHCTDVT NASRTMLFNI HSLEWDKELC DFFEIPMDLL PNVFSSSEIY GLIKTGALEG VPISGCLGDQ CAALVGQMCF QEGQAKNTYG TGCFLLCNTG RKCVFSEHGL LTTVAYKLGR EKPAYYALEG SVAIAGAVIR WLRDNLGIIE TSGDIERLAK EVGTSYGCYF VPAFSGLYAP YWEPSARGIL CGLTQFTNKC HIAFAALEAV CFQTREILEA MNRDCGIPLR HLQVDGGMTN NKVLMQLQAD ILHIPVIKPF MPETTALGAA MAAGAAEGVS VWSLEPQALS VLRMERFEPQ IQATESEIRY ATWKKAVMKS MGWVTSQSPE GGDPSIFSSL PLGFFIVSSM VMLIGARYIS GVP
Explore Glycerol kinase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets